Sensitivity of using intraoperative ultrasound using MiraQTM for the assessment of graft patency following coronary artery bypass graft (CABG) surgery, and the effect of ischaemic preconditioning on these measurements - a feasibility study for the SCORECARD project.

Not Applicable

Withdrawn

• Conditions: Coronary artery disease requiring coronary artery bypass graft surgery; Cardiovascular - Coronary heart disease

• Registration Number: ACTRN12616001115426
• Lead Sponsor: niversity of Auckland

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-08-17
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Withdrawn
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Patients will be eligible for recruitment if they meet all of the following inclusion criteria:
(1) age greater than or equal to 18 years.
(2) Admission to the cardiothoracic surgical unit (Auckland District Health Board, NZ) and expected coronary artery bypass graft surgery between 14 August 2016 and 14 October 2016.
(3) Recommended and offered elective coronary artery bypass graft surgery.
(4) Operating surgeon is the surgeon listed as an Investigator in this study.

Exclusion Criteria

Patients will not be eligible for recruitment if they meet any of the following exclusion criteria:
(1) Creatinine clearance less than or equal to 30 mL per minute.
(2) Hepatic failure as determined by Child-Pugh class B or C.
(3) BP less than or equal to 90/50 mm Hg.
(4) Undergoing coronary artery bypass graft surgery revision.
(5) Unable to provide informed consent.
(6) Not eligible for public funding.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pulsatility index obtained using the MiraQ(TM) Cardiac (Medistim, Oslow, Norway) system.[Continuous monitoring for up to two minutes immediately following anastomosis of bypass graft(s)];Flow-rate of each graft obtained using the MiraQ(TM) Cardiac (Medistim, Oslow, Norway) system.[Continuous monitoring for up to two minutes immediately following anastomosis of bypass graft(s)];Diastolic filling percentage obtained using the MiraQ(TM) Cardiac (Medistim, Oslow, Norway) system.[Continuous monitoring for up to two minutes immediately following anastomosis of bypass graft(s)]

Secondary Outcome Measures

Name	Time	Method
Mortality-rate[Percentage of all trial patients who die within the 30 day-period immediately following bypass graft surgery];Serum Troponin T level performed according to local guidelines at LabPLUS - Chemical Pathology Department.[Measurement of Troponin T in ng/L at 2,4,8,12,18,24 and 48 hours post-coronary artery bypass graft surgery]